Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725996 | 0.88 | MAPT (0.41) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1930915 | 0.84 | ALDH1A1 (0.41) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1931374 | 0.84 | MAPT (0.42) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1930776 | 0.83 | MAPT (0.43) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1932548 | 0.83 | MAPT (0.41) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1932417 | 0.82 | MAPT (0.41) | MAPTALDH1A1LMNANPC1KDM4E | |
| SCHEMBL1930914 | 0.80 | MAPT (0.51) | MAPTLMNAKDM4EKMT2AMEN1 | |
| SCHEMBL1932592 | 0.78 | MAPT (0.45) | MAPTALDH1A1NPC1KDM4ERAB9A | |
| SCHEMBL1931376 | 0.78 | RORC (0.38) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL1933051 | 0.77 | RORC (0.43) | MAPTTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633216-B2 | Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI (FR) | 2014-01-21 | — | — | US | disclosed |
| EP-1861403-B1 | NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SA (FR) | 2012-05-02 | — | — | EP | disclosed |
| US-8008321-B2 | Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-05-08 | — | — | US | disclosed |
| EP-1861403-A1 | NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097625-A1 | NOVEL IMIDAZO[1,5-A]PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | CYP3A5, CYP4B1, CYP3A7 | MAPT 2878/4885ALDH1A1 238/4885LMNA 3137/4885 |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | P2RX6, IL5, ATIC | MAPT 2116/4885ALDH1A1 711/4885LMNA 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.